Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wayfair Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $508.42 (market cap $127.55B), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.9× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Wayfair Inc for 8 Days on average.
| VRTX | W | |
|---|---|---|
Market Cap | $127.55B | $14.40B |
Volume | 1,487,944 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $119.05 |
52-Week Low | $407.37 | $57.40 |
Typical Hold Time | 120 Days | 8 Days |
Enterprise Value | $121.68B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Wayfair (W) trades at $105.70, up 1.18% today, with a bullish technical signal and strong analyst support. The stock shows positive earnings surprises in recent quarters, though it remains unprofitable with a net income margin of -2.49%. Revenue growth is modest, and the company maintains a solid gross profit margin of 30.05%. Recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook is cautiously optimistic with a consensus price target of $114.13, implying upside potential. Key risks include persistent losses, high debt-to-asset ratio, and competitive pressures. Investor sentiment is positive, but profitability challenges and macroeconomic headwinds warrant careful monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
